Analyzing Pluri (NASDAQ:PLUR) and Prime Medicine (NYSE:PRME)

Prime Medicine (NYSE:PRME) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Valuation & Earnings

This table compares Prime Medicine and Pluri”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$2.98 million	54.52	-$198.13 million	($1.65)	-0.75
Pluri	$678,000.00	40.51	-$20.89 million	($5.60)	-0.70

Pluri has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 23.5% of Prime Medicine shares are held by company insiders. Comparatively, 10.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Prime Medicine and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-107.87%	-74.97%
Pluri	-3,551.49%	-2,778.13%	-83.61%

Analyst Recommendations

This is a summary of recent ratings and target prices for Prime Medicine and Pluri, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0	0	8	1	3.11
Pluri	0	0	0	0	0.00

Prime Medicine presently has a consensus price target of $13.38, suggesting a potential upside of 978.63%. Given Prime Medicine’s stronger consensus rating and higher possible upside, research analysts clearly believe Prime Medicine is more favorable than Pluri.

Risk and Volatility

Prime Medicine has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500.

Summary

Prime Medicine beats Pluri on 13 of the 15 factors compared between the two stocks.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.